Tag: intestine cancer therapeutics market insights

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the Intestine Cancer Therapeutics market right now?

The market size of therapeutics for intestine cancer has witnessed robust growth in the recent past. This market is projected to expand from $14 billion in 2024 to $15.26 billion in 2025, manifesting a compound annual growth rate (CAGR) of 9.0%. The growth during the historical period is a result of progression in medical research, a surge in cancer cases, improved chemotherapy and radiology treatments, initiatives towards early detection and screening, along with discoveries of genetics and biomarkers.

How fast Is the intestine cancer therapeutics market expected to grow, and what’s its future value?

The market for therapeutics related to intestine cancer is projected to experience substantial growth in the upcoming years. The market is predicted to reach a value of $21.15 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.5%. This growth in the forecast period is credited to developments in immunotherapy, precision medicine and personalized treatments, the emergence of targeted therapies, and the incorporation of artificial intelligence (AI), and patient-focused methodologies. The main trends to watch in this forecast period include technologies for liquid biopsies, research in precision medicine and biomarkers, combination treatments, patient-centered care along with supportive therapies, and the use of minimally invasive surgical methods.

Get your intestine cancer therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

What are the leading drivers of growth in the intestine cancer therapeutics market?

The rising incidence of hereditary colorectal cancer syndromes is predicted to fuel the expansion of the intestine cancer therapeutics market. These syndromes consist of hereditary genetic variants that enhance a person’s susceptibility to developing colorectal cancer. Their significant contribution to intestinal cancer therapeutics lies in providing insights related to specific genetic mutations that greatly amplify colorectal cancer risk. For instance, the World Health Organization declared in July 2023 that the number of hereditary colorectal cancer cases is anticipated to significantly rise by 2040, with an estimated 3.2 million new instances and 1.6 million deaths each year. This denotes a 63% and 73% surge in new cases and fatalities respectively as compared to the present figures. Hence, the escalating incidence of hereditary colorectal cancer syndromes is a key driver of the intestine cancer therapeutics market’s growth.

Intestine Cancer Therapeutics Market Driver: Personalized Medicine Catalyzing The Growth Of The Intestine Cancer Therapeutics Market

 

What are the key segments defining the intestine cancer therapeutics market?

The intestine cancer therapeutics market covered in this report is segmented –

1) By Treatment Type: Immunotherapy, Chemotherapy, Other Treatments

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

3) By Application: Hospitals, Homecare, Specialty Centers, Other Applications

Subsegments:

1) By Immunotherapy: Checkpoint Inhibitors, CAR T-Cell Therapy, Cancer Vaccines

2) By Chemotherapy: Adjuvant Chemotherapy, Neoadjuvant Chemotherapy, Palliative Chemotherapy

3) By Other Treatments: Targeted Therapy, Radiation Therapy, Surgery, Hormone Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13231&type=smp

Who are the key players steering the development of the intestine cancer therapeutics market?

Major companies operating in the intestine cancer therapeutics market report are Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Cipla Inc., Aurobindo Pharma Limited, Lupin Limited

What emerging trends are influencing the growth of the intestine cancer therapeutics market?

Leading enterprises in the intestinal cancer therapeutics market are focusing on the creation of unique products such as Lonsurf to cater to a wider customer base and enhance their sales and revenue. LONSURF, which is a fusion of two drugs – trifluridine and tipiracil, is designed for the treatment of metastatic colorectal cancer in adults. Taiho Oncology Inc., a pharmaceutical company based in the US, was granted approval for Lonsurf by the US Food and Drug Administration in August 2023. Lonsurf is offered as a single tablet meant for oral consumption. Trifluridine serves to halt the growth of cancer cells and tipiracil enhances the effectiveness of trifluridine by preventing its breakdown inside the body. This approval makes Lonsurf a new treatment choice which potentially benefits patients with metastatic colorectal cancer and others eligible, by potentially improving their outcomes and enriching their quality of life.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13231

Which regions are most influential in expanding the intestine cancer therapeutics market?

Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Anti-Inflammatory Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Factors Are Driving the Anticipated Growth Rate of the Intestine Cancer Therapeutics Market Through 2034?

Notable growth has been observed in recent years in the market size for intestine cancer therapeutics. The market is projected to expand from a worth of $14 billion in 2024 to $15.26 billion in 2025, which represents a compound annual growth rate (CAGR) of 9.0%. The growth experienced in the historical period can be tied to improvements in medical research, higher occurrences of cancer, development in chemotherapy and radiation therapies, as well as initiatives for early detection and screening, and breakthroughs in genetic and biomarker discoveries.

The market for intestine cancer therapeutics is anticipated to witness considerable growth in the coming years, escalating to $21.15 billion in 2029, with a compound annual growth rate (CAGR) of 8.5%. This projected growth can be linked to factors such as advances in immunotherapy, precision medicine, personalized treatments, new targeted therapies, and the application of artificial intelligence (AI) in a patient-centered approach. The forecast period will likely see trends including liquid biopsy technology, research in precision medicine and biomarkers, combination treatments, approaches focused on the patient and supportive therapies, as well as the implementation of less invasive surgical methods.

Which Major Market Drivers Are Expected to Boost the intestine cancer therapeutics Market’s Growth Potential?

The rise in cases of colorectal cancer syndromes related to heredity is anticipated to stimulate the intestine cancer therapeutics market’s expansion. These syndromes, which are groups of genetic conditions, elevate a person’s chances of contracting colorectal cancer (cancer of the rectum or colon). The syndromes are crucial to intestinal cancer therapeutics as they provide data linked to particular genetic mutations, thereby markedly increasing the risk of developing colorectal cancer. For instance, the World Health Organization, an intergovernmental organization based in Switzerland, predicted in July 2023 that hereditary colorectal cancer’s occurrence is set to significantly rise by 2040, projecting approximately 3.2 million new instances and 1.6 million annual deaths. This denotes a surge of 63% new cases and 73% fatalities compared with current statistics. Consequently, the growing frequency of hereditary colorectal cancer syndromes contributes to the increase in the intestine cancer therapeutics market. A major factor driving the Intestine Cancer Therapeutics Market is the revolution brought about by personalized medicine. Personalized medicine, which adjusts medical choices, proceedings, interventions, and medications to a patient’s unique features, is witnessing a surge in demand. This practice enables treatment plans in intestine cancer therapeutics to be modified using each patient’s genetic and molecular factors, enhancing treatment efficiency and reducing side effects. For instance, in 2022, the Personalized Medicine Coalition, a professional association in the US, highlighted that the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) that year. Out of 35 therapeutic NMEs, approximately 34%, which is 12 in number, are indexed as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the escalating demand for personalized medicine contributes to the growth of the intestine cancer therapeutics market.

Request Your Free Intestine Cancer Therapeutics Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13231&type=smp

Who Are the Major Industry Leaders Accelerating Growth in the Intestine Cancer Therapeutics Market?

Major companies operating in the intestine cancer therapeutics market report are:

• Pfizer Inc._x000D_

• Johnson & Johnson Private Limited_x000D_

• Roche Holding AG_x000D_

• AbbVie Inc._x000D_

• Bayer AG_x000D_

Which Current Trends Are Having the Most Impact on the Intestine Cancer Therapeutics Market?

Leading businesses in the realm of intestine cancer therapeutics are pioneering new solutions like Lonsurf and securing endorsements to reach an expanded customer range and boost sale numbers and revenue. LONSURF is a mixture of two distinct drugs, trifluridine and tipiracil, dedicated towards the treatment of mature patients with metastatic colorectal cancer. For illustration, in August 2023, Taiho Oncology Inc., an American pharmaceutical firm, was granted approval for Lonsurf by the US Food and Drug Administration. Lonsurf is offered in the form of a singular, consumable tablet. Trifluridine functions by restraining the proliferation of cancer cells, and tipiracil augments the effectiveness of trifluridine by warding off its degradation by the human body. The clearance for Lonsurf allows patients suffering from metastatic colorectal cancer and other applicable cancers to have a novel remedial alternative that can potentially enhance results and their quality of living.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

What Are the Major Categories and Their Growth Dynamics in the Intestine Cancer Therapeutics Market?

The intestine cancer therapeutics market covered in this report is segmented –

1) By Treatment Type: Immunotherapy, Chemotherapy, Other Treatments

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

3) By Application: Hospitals, Homecare, Specialty Centers, Other Applications

Subsegments:

1) By Immunotherapy: Checkpoint Inhibitors, CAR T-Cell Therapy, Cancer Vaccines

2) By Chemotherapy: Adjuvant Chemotherapy, Neoadjuvant Chemotherapy, Palliative Chemotherapy

3) By Other Treatments: Targeted Therapy, Radiation Therapy, Surgery, Hormone Therapy

Which Regions Are Key Players in the Growth of the Intestine Cancer Therapeutics Market?

Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Scope and Reach of the Intestine Cancer Therapeutics Market Defined?

Intestine cancer therapeutics refer to the various treatment options available for small intestine and colorectal cancer that affect the digestive system. These treatments aim to remove or manage cancerous cells and improve patient outcomes. The specific treatment plan will depend on the stage of the cancer, the patient’s overall health, and other factors.

Browse Through More Similar Reports By The Business Research Company:

Anti-Inflammatory Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: